Irem Turkmen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Irem Turkmen has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Arda Güler
Department of Cardiology, University of Health Sciences, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Center, Training and Research Hospital, İstanbul, Türkiye
3 shared publications - Mehmet Erturk
Department of Cardiology, University of Health Sciences, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Center, Training and Research Hospital, İstanbul, Türkiye
3 shared publications Gamze Babur Guler
Department of Cardiology University of Health Sciences, Mehmet Akif Ersoy Thoracic Cardiovascular Surgery Training and Research Hospital Istanbul Turkey
2 shared publicationsMehmet Erturk
Department of Cardiology University of Health Sciences, Mehmet Akif Ersoy Thoracic Cardiovascular Surgery Training and Research Hospital Istanbul Turkey
2 shared publications- Serkan Kahraman
Department of Cardiology, University of Health Sciences, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey
2 shared publications - Ahmed Mohsen Mohamed Msc
Department of Cardiovascular Medicine, Cairo University, 31, 30 Street, Hadayek Helwan, Cairo, Egypt
1 shared publication
Latest Publications
- 13 November 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
A Novel Double Kissing Nano Culotte Stenting for Coronary Bifurcation Lesions: A Detailed Technical Evaluation and Clinical Outcomes
Background: Percutaneous coronary intervention (PCI) of coronary bifurcation lesions (CBL) remains one of the most technically demanding procedures in interventional cardiology, and the optimal two‐stent stratgy has yet to be established. A technique that minimizes stent overlap while ensuring complete side branch osteal scaffolding may improve procedural and clinical outcomes. Aims: Our aim in this study is to evaluate the feasibility, procedural performance, and 1‐year clinical outcomes of the novel double kissing (DK) nano culotte technique for the treatment of CBL. Methods: In this prospective, single‐center observational study, 43 patients with true de novo CBLs underwent PCI using the DK nano‐culotte technique, with OCT guidance used in 30 patients (69.7%). Eligible lesions had distal main‐vessel and side‐branch reference diameters ≥ 2.5 and ≥ 2.25 mm, respectively. Bench testing preceded first‐in‐human application, and computational fluid dynamics (CFD) analysis was performed. The primary endpoint was 1‐year target lesion failure (TLF), defined as the composite of target lesion revascularization (TLR), target vessel myocardial infarction (TVMI), and cardiac death. Results: Procedural and technical success were achieved in 100.0% and 97.6% of cases, respectively, with a mean procedure time of 48.0 ± 14.9 min. Residual diameter stenosis remained low across all treated segments, and no significant stent malapposition (> 500 μm) was identified by OCT. CFD demonstrated favorable post‐procedural hemodynamic remodeling with significant improvement in time‐averaged wall shear stress. At 1 year, TLF occurred in one patient (2.38%) owing to silent ischemia associated with in‐stent restenosis requiring repeat revascularization. No TVMI, cardiac death, or stent thrombosis was observed. Conclusions: The DK nano culotte technique demonstrated excellent procedural feasibility, precise stent optimization, favorable flow dynamics, and encouraging 1‐year clinical outcomes. These findings support further evaluation of this OCT‐guided bifurcation strategy in larger multicenter studies (DK Nano‐Culotte Stenting For Coronary Bifurcation Lesion; NCT05406284).
- 13 November 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
A Novel Double Kissing Nano Culotte Stenting for Coronary Bifurcation Lesions: A Detailed Technical Evaluation and Clinical Outcomes
Background: Percutaneous coronary intervention (PCI) of coronary bifurcation lesions (CBL) remains one of the most technically demanding procedures in interventional cardiology, and the optimal two‐stent stratgy has yet to be established. A technique that minimizes stent overlap while ensuring complete side branch osteal scaffolding may improve procedural and clinical outcomes. Aims: Our aim in this study is to evaluate the feasibility, procedural performance, and 1‐year clinical outcomes of the novel double kissing (DK) nano culotte technique for the treatment of CBL. Methods: In this prospective, single‐center observational study, 43 patients with true de novo CBLs underwent PCI using the DK nano‐culotte technique, with OCT guidance used in 30 patients (69.7%). Eligible lesions had distal main‐vessel and side‐branch reference diameters ≥ 2.5 and ≥ 2.25 mm, respectively. Bench testing preceded first‐in‐human application, and computational fluid dynamics (CFD) analysis was performed. The primary endpoint was 1‐year target lesion failure (TLF), defined as the composite of target lesion revascularization (TLR), target vessel myocardial infarction (TVMI), and cardiac death. Results: Procedural and technical success were achieved in 100.0% and 97.6% of cases, respectively, with a mean procedure time of 48.0 ± 14.9 min. Residual diameter stenosis remained low across all treated segments, and no significant stent malapposition (> 500 μm) was identified by OCT. CFD demonstrated favorable post‐procedural hemodynamic remodeling with significant improvement in time‐averaged wall shear stress. At 1 year, TLF occurred in one patient (2.38%) owing to silent ischemia associated with in‐stent restenosis requiring repeat revascularization. No TVMI, cardiac death, or stent thrombosis was observed. Conclusions: The DK nano culotte technique demonstrated excellent procedural feasibility, precise stent optimization, favorable flow dynamics, and encouraging 1‐year clinical outcomes. These findings support further evaluation of this OCT‐guided bifurcation strategy in larger multicenter studies (DK Nano‐Culotte Stenting For Coronary Bifurcation Lesion; NCT05406284).
- Open Access
- 1 January 2026
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 30 (5) , 321-332
Phenotypic, Epidemiologic, and Imaging Features of Hypertrophic Cardiomyopathy: A Single-Center Experience
The Anatolian Journal of Cardiology - Peer-reviewed cardiology journal publishing original research, reviews, case reports. Impact Factor 1.5. The Anatolian Journal of Cardiology - Leading international cardiology journal with Impact Factor 1.5. Publishing original research, reviews, and case reports in cardiovascular medicine. Indexed in PubMed, Scopus, and Web of Science.
- 1 January 2026
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 30 (5) , 321-332
Open AccessPhenotypic, Epidemiologic, and Imaging Features of Hypertrophic Cardiomyopathy: A Single-Center Experience
The Anatolian Journal of Cardiology - Peer-reviewed cardiology journal publishing original research, reviews, case reports. Impact Factor 1.5. The Anatolian Journal of Cardiology - Leading international cardiology journal with Impact Factor 1.5. Publishing original research, reviews, and case reports in cardiovascular medicine. Indexed in PubMed, Scopus, and Web of Science.
- 2 December 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 107 (2) , 683-690
The Impact of Coronary Bifurcation Angle on Cardiovascular Outcomes in Culotte Stenting Technique: The Insights From the OPTIMUM Trial
Background: Culotte stenting is one of the most preferred techniques in the percutaneous coronary intervention (PCI) of coronary bifurcation lesion (CBL). Therefore, clinical event predictors in culotte stenting are gaining importance. Bifurcation angle (BA) is an important determinant of the clinical outcomes for the PCI of CBL. Aims: Our aim in this study was to investigate the impact of BA in culotte stenting technique on cardiovascular outcomes. Methods: The OPTIMUM trial was a single‐center, observational registry. A total of 1408 PCI procedures were evaluated, and 200 patients were included. Then, patients were divided into two groups according to the BA. 157 patients with BA 70° or less were categorized as group 1, while 43 with BA more than 70° were categorized as group 2. The primary endpoint of the study was the target lesion failure (TLF) which was a composite endpoint of target vessel myocardial infarction (TVMI), target lesion revascularization (TLR) and cardiac death at 1‐ and 3‐year follow‐up periods. Results: The incidence of TLF at 1‐year (4 [2.5%]; 4 [9.3%], p = 0.048) and 3‐year [14 (8.9%); 10 (23.3%), p = 0.008] were significantly lower in patients with BA 70° or less compared to patients with BA more than 70° that was mainly driven by the TLR at 3‐year (10 [6.4%]; 8 [18.6%], p = 0.013). The incidence of TVMI (5 [3.2%]; 2 [4.7%], p = 0.648) and cardiac death (4 [2.5%]; 2 [4.7%], p = 0.458) were similar in both groups at 3‐year. Conclusion: The wider BA is associated with increased 3‐year TLR and TLF in culotte stenting technique.
- 2 December 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 107 (2) , 683-690
The Impact of Coronary Bifurcation Angle on Cardiovascular Outcomes in Culotte Stenting Technique: The Insights From the OPTIMUM Trial
Background: Culotte stenting is one of the most preferred techniques in the percutaneous coronary intervention (PCI) of coronary bifurcation lesion (CBL). Therefore, clinical event predictors in culotte stenting are gaining importance. Bifurcation angle (BA) is an important determinant of the clinical outcomes for the PCI of CBL. Aims: Our aim in this study was to investigate the impact of BA in culotte stenting technique on cardiovascular outcomes. Methods: The OPTIMUM trial was a single‐center, observational registry. A total of 1408 PCI procedures were evaluated, and 200 patients were included. Then, patients were divided into two groups according to the BA. 157 patients with BA 70° or less were categorized as group 1, while 43 with BA more than 70° were categorized as group 2. The primary endpoint of the study was the target lesion failure (TLF) which was a composite endpoint of target vessel myocardial infarction (TVMI), target lesion revascularization (TLR) and cardiac death at 1‐ and 3‐year follow‐up periods. Results: The incidence of TLF at 1‐year (4 [2.5%]; 4 [9.3%], p = 0.048) and 3‐year [14 (8.9%); 10 (23.3%), p = 0.008] were significantly lower in patients with BA 70° or less compared to patients with BA more than 70° that was mainly driven by the TLR at 3‐year (10 [6.4%]; 8 [18.6%], p = 0.013). The incidence of TVMI (5 [3.2%]; 2 [4.7%], p = 0.648) and cardiac death (4 [2.5%]; 2 [4.7%], p = 0.458) were similar in both groups at 3‐year. Conclusion: The wider BA is associated with increased 3‐year TLR and TLF in culotte stenting technique.
- 9 July 2024
- Published by Wiley in Echocardiography
- Vol. 41 (7) , e15880
Ongoing assertion of two‐dimensional measurements on differentiation type of left ventricular hypertrophy: Focus on inferior vena cava
Background: Left ventricular hypertrophy (LVH), including hypertensive LVH, hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis (CA), is a commonly encountered condition in cardiology practice, presenting challenges in differential diagnosis. In this study, we aimed to investigate the importance of echocardiographic evaluation of the inferior vena cava (IVC) in distinguishing LVH subtypes including hypertensive LVH, HCM, and CA.Methods: In this retrospective study, patients with common causes of LVH including hypertensive LVH, HCM, and CA were included. The role of echocardiographic evaluation of IVC diameter and collapsibility in distinguishing these causes of LVH was assessed in conjunction with other echocardiographic, clinical, and imaging methods.Results: A total of 211 patients (45% HCM, 43% hypertensive heart disease, and 12% CA) were included in our study. Their mean age was 56.6 years and 62% of them were male. While mean IVC diameter was significantly dilated in CA patients (13.4 mm in hypertensive LVH, 16.0 mm in HCM, and 21.1 mm in CA, p < .001), its collapsibility was reduced (IVC collapsible in 95% of hypertensive patients, 72% of HCM patients, and 12% of CA patients, p < .001). In the analysis of diagnostic probabilities, the presence of both hypovoltage and IVC dilation is significant for CA patients. Although it is not statistically significant, the presence of IVC dilation along with atrial fibrillation supports the diagnosis of HCM.Conclusion: In conclusion, although advances in imaging techniques facilitate the diagnosis of LVH, simple echocardiographic methods should never be overlooked. Our study supports the notion that IVC assessment could play an important role in the differential diagnosis of LVH.
- 9 July 2024
- Published by Wiley in Echocardiography
- Vol. 41 (7) , e15880
Ongoing assertion of two‐dimensional measurements on differentiation type of left ventricular hypertrophy: Focus on inferior vena cava
Background: Left ventricular hypertrophy (LVH), including hypertensive LVH, hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis (CA), is a commonly encountered condition in cardiology practice, presenting challenges in differential diagnosis. In this study, we aimed to investigate the importance of echocardiographic evaluation of the inferior vena cava (IVC) in distinguishing LVH subtypes including hypertensive LVH, HCM, and CA.Methods: In this retrospective study, patients with common causes of LVH including hypertensive LVH, HCM, and CA were included. The role of echocardiographic evaluation of IVC diameter and collapsibility in distinguishing these causes of LVH was assessed in conjunction with other echocardiographic, clinical, and imaging methods.Results: A total of 211 patients (45% HCM, 43% hypertensive heart disease, and 12% CA) were included in our study. Their mean age was 56.6 years and 62% of them were male. While mean IVC diameter was significantly dilated in CA patients (13.4 mm in hypertensive LVH, 16.0 mm in HCM, and 21.1 mm in CA, p < .001), its collapsibility was reduced (IVC collapsible in 95% of hypertensive patients, 72% of HCM patients, and 12% of CA patients, p < .001). In the analysis of diagnostic probabilities, the presence of both hypovoltage and IVC dilation is significant for CA patients. Although it is not statistically significant, the presence of IVC dilation along with atrial fibrillation supports the diagnosis of HCM.Conclusion: In conclusion, although advances in imaging techniques facilitate the diagnosis of LVH, simple echocardiographic methods should never be overlooked. Our study supports the notion that IVC assessment could play an important role in the differential diagnosis of LVH.
- 3 November 2023
- Published by Wiley in Echocardiography
- Vol. 41 (1)
Combination of an extremely rare and a common congenital valvular anomalies: Accessory mitral valve chordae from left atrium and bicuspid aortic valve
Accessory chordae tendineae is an extremely rare anomaly. In this case report, we described a 61‐year‐old female patient newly diagnosed with the combination of an accessory mitral valve chordae extending from left atrium which is an extremely rare congenital anomaly and a bicuspid aortic valve. In our patient, three‐dimensional echocardiography showed incremental value over two‐dimensional echocardiography in the assessment of the exact localization and the extend of accessory chordea.
- 3 November 2023
- Published by Wiley in Echocardiography
- Vol. 41 (1)
Combination of an extremely rare and a common congenital valvular anomalies: Accessory mitral valve chordae from left atrium and bicuspid aortic valve
Accessory chordae tendineae is an extremely rare anomaly. In this case report, we described a 61‐year‐old female patient newly diagnosed with the combination of an accessory mitral valve chordae extending from left atrium which is an extremely rare congenital anomaly and a bicuspid aortic valve. In our patient, three‐dimensional echocardiography showed incremental value over two‐dimensional echocardiography in the assessment of the exact localization and the extend of accessory chordea.
- 1 January 2023
- Published by Kare Publishing in Eurasian Journal of Medical Advances
- Vol. 3 (3) , 149-151
Myastenic Syndrome Diagnosed After Treatment of Small Cell Lung Cancer with Atezolizumab (PDL-1 Inhibitor)
Immune checkpoint inhibitors have been increasingly used for many type of solid tumor, first line treatment of small cell lung cancer (SCLC) with chemotherapy combination with atezolizumab is one of them. Although usually well tolerated, autoimmune related side effects can be seen.We report of autoimmune myasetnia gravis that occured after treatment of atezolizumab, an anti-programmed-death (anti-PD-1) monoclonal antibody. Our patient is 71 year old woman with extensive stage small cell lung cancer receiving chemotherapy combined with atezolizumab. Although good oncological response to treatment after 8 cycle of atezolizumab, myastenia gravis was occured. This automimmune neurological syndrome is likely associated with atezolizumab treatment, patient had no any neurological disorder before. Symptoms were partially responded after steroid, piridostigmine and iv-ig therapy. The number of the patient that treated with immunotherapy will increase in the future so it should be important to know the adverse effects management of immunotherapy.
- 1 January 2023
- Published by Kare Publishing in Eurasian Journal of Medical Advances
- Vol. 3 (3) , 149-151
Myastenic Syndrome Diagnosed After Treatment of Small Cell Lung Cancer with Atezolizumab (PDL-1 Inhibitor)
Immune checkpoint inhibitors have been increasingly used for many type of solid tumor, first line treatment of small cell lung cancer (SCLC) with chemotherapy combination with atezolizumab is one of them. Although usually well tolerated, autoimmune related side effects can be seen.We report of autoimmune myasetnia gravis that occured after treatment of atezolizumab, an anti-programmed-death (anti-PD-1) monoclonal antibody. Our patient is 71 year old woman with extensive stage small cell lung cancer receiving chemotherapy combined with atezolizumab. Although good oncological response to treatment after 8 cycle of atezolizumab, myastenia gravis was occured. This automimmune neurological syndrome is likely associated with atezolizumab treatment, patient had no any neurological disorder before. Symptoms were partially responded after steroid, piridostigmine and iv-ig therapy. The number of the patient that treated with immunotherapy will increase in the future so it should be important to know the adverse effects management of immunotherapy.
- Open Access
- 8 June 2022
- Published by Wiley
A rare bioprosthetic valve complication: Flail leaflet related to late cusp tear
Bioprosthetic valves have risk of gradual valve degeneration and dysfunction in follow-up period. In this case report, we describe a 72-year-old man who suffered from severe transvalvular mitral valve regurgitation due to isolated rupture of the bioprosthetic mitral valve without significant degeneration, calcification and thickness. We would like to emphasize this rare prosthetic valve-related complication in a 10-year-old bioprosthetic valve.
- 8 June 2022
- Published by Wiley
Open AccessA rare bioprosthetic valve complication: Flail leaflet related to late cusp tear
Bioprosthetic valves have risk of gradual valve degeneration and dysfunction in follow-up period. In this case report, we describe a 72-year-old man who suffered from severe transvalvular mitral valve regurgitation due to isolated rupture of the bioprosthetic mitral valve without significant degeneration, calcification and thickness. We would like to emphasize this rare prosthetic valve-related complication in a 10-year-old bioprosthetic valve.
- Open Access
- 15 October 2021
- Published by Trakya University Journal of Natural Sciences in Trakya University Journal of Natural Sciences
- Vol. 22 (2) , 187-197
SALBUTAMOL AMELIORATES THE PHENOTYPE OF THE SKIN INFLAMMATORY DISEASE PSORIASIS ACCORDING TO SKIN SPHEROID MODELS
Psoriasis is a multifactorial chronic inflammatory disorder resulting by the interplay of genetics, the immune system and the environment. It is characterized by the hyperproliferation of epithelial cells, generating red, itchy psoriatic plaques which have no cure but have great negative impact in patients’ life. Although corticosteroids or vitamin D analogs might help recovery to some extent, there is yet no total cure for the disease. In this study, we sought to generate three-dimensional (3D) stress-related psoriatic skin spheroids with the screening of the potential efficacy of a β2-adrenergic receptor agonist, salbutamol. 3D Culture spheroids with human dermal fibroblasts (HDF), human epithelial keratinocytes (HEK) and human monocytic cell line (THP-1) were generated as a representative model of skin and the protocol of stress-related modelling was conducted. The efficacy of the drug salbutamol was evaluated by the changes in mRNA and protein expression levels of selected genes, as well as by several metabolic assays. We developed a method for culturing spherical organoid models of psoriasis in vitro. We tested the potential theurapetic effects of salbutamol on psoriasis spheroids. Spheroids treated with salbutamol indicated the effictiveness of the treatment. 3D spheroid system was found partially efficient for mimicking the physiological features of psoriasis in vitro. This present work may be a starting point for future investigation as it is the first to generate a stress-related psoriatic model and first to try a β2 agonist as a potential treatment option. Considering the effects and suitability of topical application of salbutamol, its efficacy should not be underestimated and should be investigated further for translating this knowledge into clinics.
- 15 October 2021
- Published by Trakya University Journal of Natural Sciences in Trakya University Journal of Natural Sciences
- Vol. 22 (2) , 187-197
Open AccessSALBUTAMOL AMELIORATES THE PHENOTYPE OF THE SKIN INFLAMMATORY DISEASE PSORIASIS ACCORDING TO SKIN SPHEROID MODELS
Psoriasis is a multifactorial chronic inflammatory disorder resulting by the interplay of genetics, the immune system and the environment. It is characterized by the hyperproliferation of epithelial cells, generating red, itchy psoriatic plaques which have no cure but have great negative impact in patients’ life. Although corticosteroids or vitamin D analogs might help recovery to some extent, there is yet no total cure for the disease. In this study, we sought to generate three-dimensional (3D) stress-related psoriatic skin spheroids with the screening of the potential efficacy of a β2-adrenergic receptor agonist, salbutamol. 3D Culture spheroids with human dermal fibroblasts (HDF), human epithelial keratinocytes (HEK) and human monocytic cell line (THP-1) were generated as a representative model of skin and the protocol of stress-related modelling was conducted. The efficacy of the drug salbutamol was evaluated by the changes in mRNA and protein expression levels of selected genes, as well as by several metabolic assays. We developed a method for culturing spherical organoid models of psoriasis in vitro. We tested the potential theurapetic effects of salbutamol on psoriasis spheroids. Spheroids treated with salbutamol indicated the effictiveness of the treatment. 3D spheroid system was found partially efficient for mimicking the physiological features of psoriasis in vitro. This present work may be a starting point for future investigation as it is the first to generate a stress-related psoriatic model and first to try a β2 agonist as a potential treatment option. Considering the effects and suitability of topical application of salbutamol, its efficacy should not be underestimated and should be investigated further for translating this knowledge into clinics.
- 6 February 2019
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 47 (6) , 384-386
Three‐dimensional echocardiographic demonstration of aortic wall erosion after percutaneous atrial septal defect closure
Although late complications of percutaneous closure of atrial septal defect (ASD), including cardiac erosion and thrombosis, are rare, they are the most lethal. Data are still lacking regarding the usefulness of new imagining modalities, such as three‐dimensional echocardiography (3DE), for the detection of these complications. Here, we report the case of a 57‐year‐old woman in whom cardiac erosion was very well visualized by 3D transesophageal echocardiography (3D TEE) after percutaneous ASD closure.
- 6 February 2019
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 47 (6) , 384-386
Three‐dimensional echocardiographic demonstration of aortic wall erosion after percutaneous atrial septal defect closure
Although late complications of percutaneous closure of atrial septal defect (ASD), including cardiac erosion and thrombosis, are rare, they are the most lethal. Data are still lacking regarding the usefulness of new imagining modalities, such as three‐dimensional echocardiography (3DE), for the detection of these complications. Here, we report the case of a 57‐year‐old woman in whom cardiac erosion was very well visualized by 3D transesophageal echocardiography (3D TEE) after percutaneous ASD closure.